Skip to main content
SpringerLink
Log in

Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention

  • Interventional Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

We evaluated the role of the activated clotting time (ACT) and activated partial thromboplastin time (APTT), both currently available as bedside tests, for monitoring anticoagulation following bolus injection of 2500 or 5000 IU heparin in 21 patients undergoing neuroradiological procedures. APTT was measured using the CoaguChek Pro device compared to the laboratory standard measurement and ACT comparing CoaguChek Pro to Hemochron Celite and Kaolin. Statistical analysis was performed using Bablok-Passing regression. Despite heparin doses of 2500–5000 IU APTT measurements were out of range in 67% of patients using CoaguChek Pro and in 76.5% of patients using the laboratory measurement. ACT was reliably determined in all patients. The correlation between the different devices (CoaguChek Pro vs. Hemochron Celite r=0.69, Kaolin r=0.78) and assays (Hemochron Celite/Kaolin r=0.85) was good. ACT ranged from 141–417 s measured by CoaguChek Pro and 138–320 s measured by Hemochron Celite and 172–381 s using Hemochron Kaolin. These results indicate that ACT is the method of choice for monitoring anticoagulation in neuroangiographic procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berlis A, Schumacher M (1999) Antikoagulationskontrolle bei neuroradiologisch Interventionellen Eingriffen mit ACT. Fortschr Röntgenstr 170: 378–383

    Google Scholar 

  2. Fujii Y, Takeuchi S, Koike T, et al (1994) Heparin administration and monitoring for neuroangiography. AJNR 15: 51–54

    CAS  Google Scholar 

  3. Scott JA, Berenstein A, Blumenthal D (1986) Use of the activated clotting time as a measure of anticoagulation during interventional procedures. Radiology 158: 849–850

    CAS  PubMed  Google Scholar 

  4. Simko RJ, Tsung FFW, Stanek EJ (1995) Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 29: 1015–1021

    CAS  PubMed  Google Scholar 

  5. Reiner JS, Coyne KS, Lundergan CF, Ross AM (1994) Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 32: 49–52

    CAS  PubMed  Google Scholar 

  6. Banez EI, Triplett DA, Koepke J (1980) Laboratory monitoring of heparin therapy. The effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol 74: 569–574

    CAS  PubMed  Google Scholar 

  7. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ (1992) Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 26: 260–263

    CAS  PubMed  Google Scholar 

  8. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB (1989) Adequate heparinisation during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn 18: 206–209

    CAS  PubMed  Google Scholar 

  9. Grill HP, Spero JE, Granato JE (1993) Comparison of activated partial thromboplastin time to activated clotting time for adequacy of heparin anticoagulation just before percutaneous transluminal coronary angioplasty. Am J Cardiol 71: 1219–1220

    CAS  PubMed  Google Scholar 

  10. Varah N, Smith J, Baugh RF (1990) Heparin monitoring in the coronary care unit after percutaneous transluminal angioplasty. Heart Lung 19: 265–270

    CAS  PubMed  Google Scholar 

  11. Noureddine SN (1995) Research review: use of activated clotting time to monitor Heparin therapy in coronary patients. Am J Critical Care 4: 272–277

    CAS  Google Scholar 

  12. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR (1994) Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 23: 1061–1065

    CAS  PubMed  Google Scholar 

  13. Kaluski E, Krakover R, Cotter G, et al (2000) Minimal heparinization in coronary angioplasty- how much heparin is really warranted? Am J Cardiol 85: 953–956

    Article  CAS  PubMed  Google Scholar 

  14. Narins CR, Hillegass WB, Nelson CL, et al (1996) Relationship between activated clotting time during angioplasty and abrupt closure. Circulation 93: 667–671

    CAS  PubMed  Google Scholar 

  15. Dion JE, Gates PC, Fox AJ, Barnett HJ, Blom RJ (1987) Clinical events following neuroangiography: a prospective study. Stroke 18: 997–1004

    CAS  PubMed  Google Scholar 

  16. Earnest F, Forbes G, Sandok BA, et al (1984) Complications of cerebral angiography: prospective assessment of risk. Am J Roentgenol 142: 247–253

    PubMed  Google Scholar 

  17. Grzyska U, Freitag J, Zeumer H (1990) Selective cerebral intraarterial DAS: complication rate and control of risk factors. Neuroradiology 32: 296–299

    CAS  PubMed  Google Scholar 

  18. Heisermann JE, Dean BL, Hodak JA, et al (1994) Neurologic complications of cerebral angiography. AJNR 15: 1401–1407

    CAS  PubMed  Google Scholar 

  19. Gabrielsen TO (1994) Neurologic complications of cerebral angiography. AJNR 15: 1408–1411

    Google Scholar 

  20. Kachel R, Jahn U, Schiffmann R, Basche S (1991) Komplikationen bei zerebraler Angiographie. Eine Studie über 6698 zerebrale Angiographien. Rev Med Chir Soc Med Nat Lasi 95: 97–105

    CAS  Google Scholar 

  21. Cronqvist M, Pierot L, Boulin A, Cognard C, Castaings L, Moret J (1998) Local intraarterial fibrinolysis of thromboemboli occurring during endovascular treatment of intracerebral aneurysm: a comparison of anatomic results and clinical outcome. AJNR 19: 157–165

    CAS  Google Scholar 

  22. American Society of Interventional and Therapeutic Neuroradiology (2001) Standards of practice. AJNR [Suppl] 22: S2

  23. Ferguson JJ, Dohmen P, Wilson JM (1995) Results of a national survey on anticoagulation for PTCA. J Inv Cardiol 7: 136

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Academic Teaching Hospital Harlaching, Sanatoriumsplatz 2, 81545, München, Germany

    R. Kubalek

  2. Section of Neuroradiology, University Hospital Freiburg, Freiburg, Germany

    R. Kubalek, A. Berlis, J. Klisch & M. Schumacher

  3. Roche Diagnostics, Mannheim, Germany

    M. Schwab

Authors
  1. R. Kubalek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Berlis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Klisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Kubalek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kubalek, R., Berlis, A., Schwab, M. et al. Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention. Neuroradiology 45, 325–327 (2003). https://doi.org/10.1007/s00234-003-0975-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-003-0975-3

Keywords

Search

Navigation